NCT02569476 2024-10-26BGB 3111 in Combination With Obinutuzumab in Participants With B-Cell Lymphoid MalignanciesBeiGenePhase 1 Completed119 enrolled 34 charts
NCT04245722 2023-10-26FT596 as a Monotherapy and in Combination With Anti-CD20 Monoclonal AntibodiesFate TherapeuticsPhase 1 Terminated98 enrolled